Better Therapeutics Announces Upcoming Poster Presentation At EASL Congress 2023 In Austria, To Include Findings From Non-alcohol Related Fatty Liver Disease Feasibility Study
Portfolio Pulse from Benzinga Newsdesk
Better Therapeutics (BTTX) will present a poster at the EASL Congress 2023 in Austria, showcasing findings from a feasibility study on non-alcohol related fatty liver disease.
June 16, 2023 | 8:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Better Therapeutics' upcoming poster presentation at EASL Congress 2023 may generate interest in the company's research on non-alcohol related fatty liver disease.
The presentation of Better Therapeutics' findings at a prestigious event like the EASL Congress 2023 will likely generate interest in the company's research and potentially attract investors. This could have a positive short-term impact on BTTX's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100